Mast cells as targets for immunotherapy of solid tumors

Molecular Immunology

Volumn 63, Issue 1, 2015, Pages 113-124

  Oldford, Sharon A ^a   Marshall, Jean S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cell recruitment; Chemokines; Histamine; Immunotherapy; Mast cells; Tumor immunology

Indexed keywords

ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CELL ACTIVATION; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; DENDRITIC CELL; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; MAST CELL; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT; CELL COMMUNICATION; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NEOPLASMS; PROCEDURES;

CELL COMMUNICATION; COMBINED MODALITY THERAPY; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MAST CELLS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84908456477     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.02.020     Document Type: Review

References (195)

1. Abdel-Majid R.M., Marshall J.S. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J. Immunol. 2004, 172:1227-1236.
2. Adams W.J., Lawson J.A., Morris D.L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994, 35:1632-1636.
3. Agarwala S.S., Glaspy J., O'Day S.J., Mitchell M., Gutheil J., Whitman E., Gonzalez R., Hersh E., Feun L., Belt R., Meyskens F., Hellstrand K., Wood D., Kirkwood J.M., Gehlsen K.R., Naredi P. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 2002, 20:125-133.
4. Akazawa T., Masuda H., Saeki Y., Matsumoto M., Takeda K., Tsujimura K., Kuzushima K., Takahashi T., Azuma I., Akira S., Toyoshima K., Seya T. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res. 2004, 64:757-764.
5. Antsiferova M., Martin C., Huber M., Feyerabend T.B., Forster A., Hartmann K., Rodewald H.R., Hohl D., Werner S. Mast cells are dispensable for normal and activin-promoted wound healing and skin carcinogenesis. J. Immunol. 2013, 191:6147-6155. 10.4049/jimmunol.1301350.
6. Benitez-Bribiesca L., Wong A., Utrera D., Castellanos E. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J. Histochem. Cytochem. 2001, 49:1061-1062.
7. Benyon R.C., Bissonnette E.Y., Befus A.D. Tumor necrosis factor-alpha dependent cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies. J. Immunol. 1991, 147:2253-2258.
8. Blatner N.R., Bonertz A., Beckhove P., Cheon E.C., Krantz S.B., Strouch M., Weitz J., Koch M., Halverson A.L., Bentrem D.J., Khazaie K. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6430-6435. 10.1073/pnas.0913683107.
9. Brett J., Gerlach H., Nawroth P., Steinberg S., Godman G., Stern D. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J. Exp. Med. 1989, 169:1977-1991.
10. Brown M.G., McAlpine S.M., Huang Y.Y., Haidl I.D., Al-Afif A., Marshall J.S., Anderson R. RNA sensors enable human mast cell anti-viral chemokine production and IFN-mediated protection in response to antibody-enhanced dengue virus infection. PLoS ONE 2012, 7:e34055. 10.1371/journal.pone.0034055.
11. Brune M., Hansson M., Mellqvist U.H., Hermodsson S., Hellstrand K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur. J. Haematol. 1996, 57:312-319.
12. Brune M., Castaigne S., Catalano J., Gehlsen K., Ho A.D., Hofmann W.K., Hogge D.E., Nilsson B., Or R., Romero A.I., Rowe J.M., Simonsson B., Spearing R., Stadtmauer E.A., Szer J., Wallhult E., Hellstrand K. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006, 108:88-96. 10.1182/blood-2005-10-4073.
13. Burke S.M., Issekutz T.B., Mohan K., Lee P.W., Shmulevitz M., Marshall J.S. Human mast cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8-dependent mechanism. Blood 2008, 111:5467-5476. 10.1182/blood-2007-10-118547.
14. Burtin C., Scheinmann P., Salomon J.C., Lespinats G., Canu P. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br. J. Cancer 1982, 45:54-60.
15. Butt A.Q., Mills K.H. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2013, 10.1038/onc.2013.432.
16. Byrne S.N., Beaugie C., O'Sullivan C., Leighton S., Halliday G.M. The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am. J. Pathol. 2011, 179:211-222. 10.1016/j.ajpath.2011.03.010.
17. Calboli F.C., Cox D.G., Buring J.E., Gaziano J.M., Ma J., Stampfer M., Willett W.C., Tworoger S.S., Hunter D.J., Camargo C.A., Michaud D.S. Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. J. Natl. Cancer Inst. 2011, 103:1588-1595. 10.1093/jnci/djr361.
18. Chan J.K., Magistris A., Loizzi V., Lin F., Rutgers J., Osann K., DiSaia P.J., Samoszuk M. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol. Oncol. 2005, 99:20-25. 10.1016/j.ygyno.2005.05.042.
19. Chan J.K., Roth J., Oppenheim J.J., Tracey K.J., Vogl T., Feldmann M., Horwood N., Nanchahal J. Alarmins: awaiting a clinical response. J. Clin. Invest. 2012, 122:2711-2719. 10.1172/JCI62423.
20. Collington S.J., Hallgren J., Pease J.E., Jones T.G., Rollins B.J., Westwick J., Austen K.F., Williams T.J., Gurish M.F., Weller C.L. The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo. J. Immunol. 2010, 184:6114-6123. 10.4049/jimmunol.0904177.
21. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G.H., Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999, 13:1382-1397.
22. Cowden J.M., Zhang M., Dunford P.J., Thurmond R.L. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J. Invest. Dermatol. 2010, 130:1023-1033. 10.1038/jid.2009.358.
23. Cowden J.M., Yu F., Banie H., Farahani M., Ling P., Nguyen S., Riley J.P., Zhang M., Zhu J., Dunford P.J., Thurmond R.L. The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann. Rheum. Dis. 2013, 10.1136/annrheumdis-2013-203832.
24. Dawicki W., Marshall J.S. New and emerging roles for mast cells in host defence. Curr. Opin. Immunol. 2007, 19:31-38. 10.1016/j.coi.2006.11.006.
25. Dawicki W., Jawdat D.W., Xu N., Marshall J.S. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J. Immunol. 2010, 184:2116-2123. 10.4049/jimmunol.0803894.
26. De Filippo K., Dudeck A., Hasenberg M., Nye E., van Rooijen N., Hartmann K., Gunzer M., Roers A., Hogg N. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 2013, 121:4930-4937. 10.1182/blood-2013-02-486217.
27. de Vries V.C., Wasiuk A., Bennett K.A., Benson M.J., Elgueta R., Waldschmidt T.J., Noelle R.J. Mast cell degranulation breaks peripheral tolerance. Am. J. Transplant. 2009, 9:2270-2280. 10.1111/j.1600-6143.2009.02755.x.
28. de Vries V.C., Pino-Lagos K., Nowak E.C., Bennett K.A., Oliva C., Noelle R.J. Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 2011, 35:550-561. 10.1016/j.immuni.2011.09.012.
29. del Rio R., Noubade R., Saligrama N., Wall E.H., Krementsov D.N., Poynter M.E., Zachary J.F., Thurmond R.L., Teuscher C. Histamine H4 receptor optimizes T regulatory cell frequency and facilitates anti-inflammatory responses within the central nervous system. J. Immunol. 2012, 188:541-547. 10.4049/jimmunol.1101498.
30. Dery R.E., Lin T.J., Befus A.D., Milne C.D., Moqbel R., Menard G., Bissonnette E.Y. Redundancy or cell-type-specific regulation? Tumour necrosis factor in alveolar macrophages and mast cells. Immunology 2000, 99:427-434.
31. Di Nardo A., Vitiello A., Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 2003, 170:2274-2278.
32. Drobits B., Holcmann M., Amberg N., Swiecki M., Grundtner R., Hammer M., Colonna M., Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 2012, 122:575-585. 10.1172/JCI61034.
33. Dudeck A., Dudeck J., Scholten J., Petzold A., Surianarayanan S., Kohler A., Peschke K., Vohringer D., Waskow C., Krieg T., Muller W., Waisman A., Hartmann K., Gunzer M., Roers A. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 2011, 34:973-984. 10.1016/j.immuni.2011.03.028.
34. + channel KCa3.1 in human lung mast cells and attenuates their migration. Eur. J. Immunol. 2008, 38:2548-2556. 10.1002/eji.200738106.
35. Dvorak A.M. Mast cell-derived mediators of enhanced microvascular permeability, vascular permeability factor/vascular endothelial growth factor, histamine, and serotonin, cause leakage of macromolecules through a new endothelial cell permeability organelle, the vesiculo-vacuolar organelle. Chem. Immunol. Allergy 2005, 85:185-204. 10.1159/000086517.
36. Dvorak A.M., Kissell S. Granule changes of human skin mast cells characteristic of piecemeal degranulation and associated with recovery during wound healing in situ. J. Leukoc. Biol. 1991, 49:197-210.
37. Enoksson M., Lyberg K., Moller-Westerberg C., Fallon P.G., Nilsson G., Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J. Immunol. 2011, 186:2523-2528. 10.4049/jimmunol.1003383.
38. Feyerabend T.B., Weiser A., Tietz A., Stassen M., Harris N., Kopf M., Radermacher P., Moller P., Benoist C., Mathis D., Fehling H.J., Rodewald H.R. Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity 2011, 35:832-844. 10.1016/j.immuni.2011.09.015.
39. Fischer M., Juremalm M., Olsson N., Backlin C., Sundstrom C., Nilsson K., Enblad G., Nilsson G. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int. J. Cancer 2003, 107:197-201. 10.1002/ijc.11370.
40. Fischer M., Harvima I.T., Carvalho R.F., Moller C., Naukkarinen A., Enblad G., Nilsson G. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J. Clin. Invest. 2006, 116:2748-2756. 10.1172/JCI24274.
41. Fleischmann A., Schlomm T., Kollermann J., Sekulic N., Huland H., Mirlacher M., Sauter G., Simon R., Erbersdobler A. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009, 69:976-981. 10.1002/pros.20948.
42. + T regulatory cell suppressor function via histamine H1 receptor interaction. J. Immunol. 2009, 183:3014-3022. 10.4049/jimmunol.0802509.
43. Fu S.L., Pierre J., Smith-Norowitz T.A., Hagler M., Bowne W., Pincus M.R., Mueller C.M., Zenilman M.E., Bluth M.H. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin. Exp. Immunol. 2008, 153:401-409. 10.1111/j.1365-2249.2008.03726.x.
44. Galli S.J., Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J. Dermatol. Sci. 2008, 49:7-19. 10.1016/j.jdermsci.2007.09.009.
45. Galli S.J., Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur. J. Immunol. 2010, 40:1843-1851. 10.1002/eji.201040559.
46. Galli S.J., Tsai M., Wershil B.K. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am. J. Pathol. 1993, 142:965-974.
47. Ganeshan K., Bryce P.J. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-beta. J. Immunol. 2012, 188:594-603. 10.4049/jimmunol.1102389.
48. Ghiringhelli F., Bruchard M., Chalmin F., Rebe C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J. Biomed. Biotechnol. 2012, 2012:473712. 10.1155/2012/473712.
49. Gomi K., Zhu F.G., Marshall J.S. Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism. J. Immunol. 2000, 165:6545-6552.
50. Gould H.J., Mackay G.A., Karagiannis S.N., O'Toole C.M., Marsh P.J., Daniel B.E., Coney L.R., Zurawski V.R., Joseph M., Capron M., Gilbert M., Murphy G.F., Korngold R. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur. J. Immunol. 1999, 29:3527-3537. 10.1002/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5.
51. Gounaris E., Erdman S.E., Restaino C., Gurish M.F., Friend D.S., Gounari F., Lee D.M., Zhang G., Glickman J.N., Shin K., Rao V.P., Poutahidis T., Weissleder R., McNagny K.M., Khazaie K. Mast cells are an essential hematopoietic component for polyp development. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19977-19982. 10.1073/pnas.0704620104.
52. + regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008, 29:771-781. 10.1016/j.immuni.2008.08.018.
53. Grimbaldeston M.A., Chen C.C., Piliponsky A.M., Tsai M., Tam S.Y., Galli S.J. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am. J. Pathol. 2005, 167:835-848. 10.1016/S0002-9440(10)62055-X.
54. Groot Kormelink T., Abudukelimu A., Redegeld F.A. Mast cells as target in cancer therapy. Curr. Pharm. Des. 2009, 15:1868-1878.
55. Gruber B.L., Marchese M.J., Kew R.R. Transforming growth factor-beta 1 mediates mast cell chemotaxis. J. Immunol. 1994, 152:5860-5867.
56. Gruber B.L., Marchese M.J., Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995, 86:2488-2493.
57. Gulliksson M., Carvalho R.F., Ulleras E., Nilsson G. Mast cell survival and mediator secretion in response to hypoxia. PLoS ONE 2010, 5:e12360. 10.1371/journal.pone.0012360.
58. Haidl I.D., McAlpine S.M., Marshall J.S. Enhancement of mast cell IL-6 production by combined toll-like and nucleotide-binding oligomerization domain-like receptor activation. Int. Arch. Allergy Immunol. 2011, 154:227-235. 10.1159/000321109.
59. Halova I., Draberova L., Draber P. Mast cell chemotaxis - chemoattractants and signaling pathways. Front. Immunol. 2012, 3:119. 10.3389/fimmu.2012.00119.
60. Hammad H., Kool M., Soullie T., Narumiya S., Trottein F., Hoogsteden H.C., Lambrecht B.N. Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J. Exp. Med. 2007, 204:357-367. 10.1084/jem.20061196.
61. Hartmann K., Henz B.M., Kruger-Krasagakes S., Kohl J., Burger R., Guhl S., Haase I., Lippert U., Zuberbier T. C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997, 89:2863-2870.
62. Hedstrom G., Berglund M., Molin D., Fischer M., Nilsson G., Thunberg U., Book M., Sundstrom C., Rosenquist R., Roos G., Erlanson M., Amini R.M., Enblad G. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br. J. Haematol. 2007, 138:68-71. 10.1111/j.1365-2141.2007.06612.x.
63. Hellstrand K., Hermodsson S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand. J. Immunol. 1991, 34:741-752.
64. Hellstrand K., Asea A., Hermodsson S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. J. Leukoc. Biol. 1994, 55:392-397.
65. Hellstrand K., Hermodsson S., Brune M., Naredi P., Carneskog J., Mellqvist U.H. Histamine in cancer immunotherapy. Scand. J. Clin. Lab. Invest. 1997, 57:193-202.
66. Horny H.P., Menke D.M., Kaiserling E. Neoplastic human tissue mast cells express the adhesion molecule CD44/HCAM. Virchows Arch. 1996, 429:91-94.
67. Hsieh C.L., Liu S.J., Shen C.R., Chen M.Y., Hsu S.C., Tsai J.P., Li Y.S., Yang C.J., Chong P., Chen H.W. IL-6-transfected tumor cells modulate the status of CD8(+) and CD4(+) T cells to control tumor growth. Immunobiology 2010, 215:486-491. 10.1016/j.imbio.2009.07.003.
68. Hsu C.L., Neilsen C.V., Bryce P.J. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 2010, 5:e11944. 10.1371/journal.pone.0011944.
69. Huang B., Lei Z., Zhang G.M., Li D., Song C., Li B., Liu Y., Yuan Y., Unkeless J., Xiong H., Feng Z.H. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008, 112:1269-1279. 10.1182/blood-2008-03-147033.
70. Iida N., Nakamoto Y., Baba T., Kakinoki K., Li Y.Y., Wu Y., Matsushima K., Kaneko S., Mukaida N. Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. J. Leukoc. Biol. 2008, 84:1001-1010. 10.1189/jlb.1107791.
71. Janikashvili N., Bonnotte B., Katsanis E., Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin. Dev. Immunol. 2011, 2011:430394. 10.1155/2011/430394.
72. Jawdat D.M., Rowden G., Marshall J.S. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J. Immunol. 2006, 177:1755-1762.
73. Jensen-Jarolim E., Achatz G., Turner M.C., Karagiannis S., Legrand F., Capron M., Penichet M.L., Rodriguez J.A., Siccardi A.G., Vangelista L., Riemer A.B., Gould H. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008, 63:1255-1266. 10.1111/j.1398-9995.2008.01768.x.
74. Johansson A., Rudolfsson S., Hammarsten P., Halin S., Pietras K., Jones J., Stattin P., Egevad L., Granfors T., Wikstrom P., Bergh A. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am. J. Pathol. 2010, 177:1031-1041. 10.2353/ajpath.2010.100070.
75. Jovanovic I.P., Pejnovic N.N., Radosavljevic G.D., Pantic J.M., Milovanovic M.Z., Arsenijevic N.N., Lukic M.L. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 2013, 10.1002/ijc.28481.
76. Jutel M., Watanabe T., Klunker S., Akdis M., Thomet O.A., Malolepszy J., Zak-Nejmark T., Koga R., Kobayashi T., Blaser K., Akdis C.A. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001, 413:420-425. 10.1038/35096564.
77. Kaczanowska S., Joseph A.M., Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 2013, 93:847-863. 10.1189/jlb.1012501.
78. Kanbe N., Kurosawa M., Nagata H., Yamashita T., Kurimoto F., Miyachi Y. Production of fibrogenic cytokines by cord blood-derived cultured human mast cells. J. Allergy Clin. Immunol. 2000, 106:S85-S90.
79. Kandere-Grzybowska K., Letourneau R., Kempuraj D., Donelan J., Poplawski S., Boucher W., Athanassiou A., Theoharides T.C. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J. Immunol. 2003, 171:4830-4836.
80. Kankkunen J.P., Harvima I.T., Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int. J. Cancer 1997, 72:385-388.
81. Karagiannis S.N., Wang Q., East N., Burke F., Riffard S., Bracher M.G., Thompson R.G., Durham S.R., Schwartz L.B., Balkwill F.R., Gould H.J. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur. J. Immunol. 2003, 33:1030-1040. 10.1002/eji.200323185.
82. Karagiannis P., Singer J., Hunt J., Gan S.K., Rudman S.M., Mechtcheriakova D., Knittelfelder R., Daniels T.R., Hobson P.S., Beavil A.J., Spicer J., Nestle F.O., Penichet M.L., Gould H.J., Jensen-Jarolim E., Karagiannis S.N. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother. 2009, 58:915-930. 10.1007/s00262-008-0607-1.
83. Kato A., Chustz R.T., Ogasawara T., Kulka M., Saito H., Schleimer R.P., Matsumoto K. Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells. J. Immunol. 2009, 182:7233-7243. 10.4049/jimmunol.0801375.
84. Kim Y.J., Hong K.S., Chung J.W., Kim J.H., Hahm K.B. Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev. Res. 2010, 3:1314-1333. 10.1158/1940-6207.CAPR-09-0272.
85. Kmiecik T., Otocka-Kmiecik A., Gorska-Ciebiada M., Ciebiada M. T lymphocytes as a target of histamine action. Arch. Med. Sci. 2012, 8:154-161. 10.5114/aoms.2012.27295.
86. Kruger-Krasagakes S., Moller A., Kolde G., Lippert U., Weber M., Henz B.M. Production of interleukin-6 by human mast cells and basophilic cells. J. Invest. Dermatol. 1996, 106:75-79.
87. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., Moons L., Wei S., Zou L., Machelon V., Emilie D., Terrassa M., Lackner A., Curiel T.J., Carmeliet P., Zou W. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005, 65:465-472.
88. Krysko O., Love Aaes T., Bachert C., Vandenabeele P., Krysko D.V. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013, 4:e631. 10.1038/cddis.2013.156.
89. Kwok E., Everingham S., Zhang S., Greer P.A., Allingham J.S., Craig A.W. FES kinase promotes mast cell recruitment to mammary tumors via the stem cell factor/KIT receptor signaling axis. Mol. Cancer Res. 2012, 10:881-891. 10.1158/1541-7786.MCR-12-0115.
90. Le H., Kim W., Kim J., Cho H.R., Kwon B. Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies. Front. Immunol. 2013, 4:104. 10.3389/fimmu.2013.00104.
91. Leal-Berumen I., O'Byrne P., Gupta A., Richards C.D., Marshall J.S. Prostanoid enhancement of interleukin-6 production by rat peritoneal mast cells. J. Immunol. 1995, 154:4759-4767.
92. Lee J.J., Natsuizaka M., Ohashi S., Wong G.S., Takaoka M., Michaylira C.Z., Budo D., Tobias J.W., Kanai M., Shirakawa Y., Naomoto Y., Klein-Szanto A.J., Haase V.H., Nakagawa H. Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis 2010, 31:427-434. 10.1093/carcin/bgp326.
93. Lin T.J., Issekutz T.B., Marshall J.S. SDF-1 induces IL-8 production and transendothelial migration of human cord blood-derived mast cells. Int. Arch. Allergy Immunol. 2001, 124:142-145. doi:53693.
94. Lin G., Wang J., Lao X., Wang J., Li L., Li S., Zhang J., Dong Y., Chang A.E., Li Q., Li S. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J. Immunother. 2012, 35:337-343. 10.1097/CJI.0b013e318255ada3.
95. Lu L.F., Lind E.F., Gondek D.C., Bennett K.A., Gleeson M.W., Pino-Lagos K., Scott Z.A., Coyle A.J., Reed J.L., Van Snick J., Strom T.B., Zheng X.X., Noelle R.J. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442:997-1002. 10.1038/nature05010.
96. Ma Y., Conforti R., Aymeric L., Locher C., Kepp O., Kroemer G., Zitvogel L. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev. 2011, 30:71-82. 10.1007/s10555-011-9283-2.
97. Maltby S., Khazaie K., McNagny K.M. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim. Biophys. Acta 2009, 1796:19-26. 10.1016/j.bbcan.2009.02.001.
98. Marshall J.S. Mast-cell responses to pathogens. Nat. Rev. Immunol. 2004, 4:787-799. 10.1038/nri1460.
99. Massari N.A., Medina V.A., Cricco G.P., Martinel Lamas D.J., Sambuco L., Pagotto R., Ventura C., Ciraolo P.J., Pignataro O., Bergoc R.M., Rivera E.S. Antitumor activity of histamine and clozapine in a mouse experimental model of human melanoma. J. Dermatol. Sci. 2013, 72:252-262. 10.1016/j.jdermsci.2013.07.012.
100. Matsuo Y., Ochi N., Sawai H., Yasuda A., Takahashi H., Funahashi H., Takeyama H., Tong Z., Guha S. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int. J. Cancer 2009, 124:853-861. 10.1002/ijc.24040.
101. Matsushima H., Yamada N., Matsue H., Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J. Immunol. 2004, 173:531-541.
102. McAlpine S.M., Issekutz T.B., Marshall J.S. Virus stimulation of human mast cells results in the recruitment of CD56(+) T cells by a mechanism dependent on CCR5 ligands. FASEB J. 2012, 26:1280-1289. 10.1096/fj.11-188979.
103. McCurdy J.D., Olynych T.J., Maher L.H., Marshall J.S. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 2003, 170:1625-1629.
104. McLachlan J.B., Shelburne C.P., Hart J.P., Pizzo S.V., Goyal R., Brooking-Dixon R., Staats H.F., Abraham S.N. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat. Med. 2008, 14:536-541. 10.1038/nm1757.
105. Meininger C.J., Yano H., Rottapel R., Bernstein A., Zsebo K.M., Zetter B.R. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 1992, 79:958-963.
106. Melillo R.M., Guarino V., Avilla E., Galdiero M.R., Liotti F., Prevete N., Rossi F.W., Basolo F., Ugolini C., de Paulis A., Santoro M., Marone G. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 2010, 29:6203-6215. 10.1038/onc.2010.348.
107. Michel A., Schuler A., Friedrich P., Doner F., Bopp T., Radsak M., Hoffmann M., Relle M., Distler U., Kuharev J., Tenzer S., Feyerabend T.B., Rodewald H.R., Schild H., Schmitt E., Becker M., Stassen M. Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cells. J. Immunol. 2013, 190:5534-5544. 10.4049/jimmunol.1203355.
108. Mohtasham N., Babakoohi S., Salehinejad J., Montaser-Kouhsari L., Shakeri M.T., Shojaee S., Sistani N.S., Firooz A. Mast cell density and angiogenesis in oral dysplastic epithelium and low- and high-grade oral squamous cell carcinoma. Acta Odontol. Scand. 2010, 68:300-304. 10.3109/00016357.2010.494622.
109. Mortaz E., Redegeld F.A., Nijkamp F.P., Wong H.R., Engels F. Acetylsalicylic acid-induced release of HSP70 from mast cells results in cell activation through TLR pathway. Exp. Hematol. 2006, 34:8-18. 10.1016/j.exphem.2005.10.012.
110. Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39:61-73. 10.1016/j.immuni.2013.07.005.
111. Murata T., Aritake K., Matsumoto S., Kamauchi S., Nakagawa T., Hori M., Momotani E., Urade Y., Ozaki H. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19802-19807. 10.1073/pnas.1110011108.
112. Nagai Y., Tanaka Y., Kuroishi T., Sato R., Endo Y., Sugawara S. Histamine reduces susceptibility to natural killer cells via down-regulation of NKG2D ligands on human monocytic leukaemia THP-1 cells. Immunology 2012, 136:103-114. 10.1111/j.1365-2567.2012.03565.x.
113. Nakae S., Suto H., Iikura M., Kakurai M., Sedgwick J.D., Tsai M., Galli S.J. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 2006, 176:2238-2248.
114. Nakasone Y., Fujimoto M., Matsushita T., Hamaguchi Y., Huu D.L., Yanaba M., Sato S., Takehara K., Hasegawa M. Host-derived MCP-1 and MIP-1alpha regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. Am. J. Pathol. 2012, 180:365-374. 10.1016/j.ajpath.2011.09.005.
115. Nakayama T., Mutsuga N., Yao L., Tosato G. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J. Leukoc. Biol. 2006, 79:95-104. 10.1189/jlb.0405226.
116. Negri E., Bosetti C., La Vecchia C., Levi F., Tomei F., Franceschi S. Allergy and other selected diseases and risk of colorectal cancer. Eur. J. Cancer 1999, 35:1838-1841.
117. Nigrovic P.A., Gray D.H., Jones T., Hallgren J., Kuo F.C., Chaletzky B., Gurish M., Mathis D., Benoist C., Lee D.M. Genetic inversion in mast cell-deficient (Wsh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am. J. Pathol. 2008, 173:1693-1701. 10.2353/ajpath.2008.080407.
118. Nilsson G., Butterfield J.H., Nilsson K., Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J. Immunol. 1994, 153:3717-3723.
119. Niyonsaba F., Iwabuchi K., Someya A., Hirata M., Matsuda H., Ogawa H., Nagaoka I. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002, 106:20-26. 10.1046/j.1365-2567.2002.01398.x.
120. Noubade R., Milligan G., Zachary J.F., Blankenhorn E.P., del Rio R., Rincon M., Teuscher C. Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice. J. Clin. Invest. 2007, 117:3507-3518. 10.1172/JCI32792.
121. Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 2010, 10:323. 10.1186/1471-2407-10-323.
122. Oka T., Kalesnikoff J., Starkl P., Tsai M., Galli S.J. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab. Invest. 2012, 92:1472-1482. 10.1038/labinvest.2012.116.
123. Okayama Y., Kirshenbaum A.S., Metcalfe D.D. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma. J. Immunol. 2000, 164:4332-4339.
124. Okayama Y., Hagaman D.D., Metcalfe D.D. A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. J. Immunol. 2001, 166:4705-4712.
125. Oldford S., Marshall J. Mast Cell Modulation of the Tumor Microenvironment 2013, 479-509. Springer, Netherlands. 10.1007/978-94-007-6217-6_20. M.R. Shurin, V. Umansky, A. Malyguine (Eds.).
126. Oldford S.A., Haidl I.D., Howatt M.A., Leiva C.A., Johnston B., Marshall J.S. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J. Immunol. 2010, 185:7067-7076. 10.4049/jimmunol.1001137.
127. Olson S.H., Hsu M., Satagopan J.M., Maisonneuve P., Silverman D.T., Lucenteforte E., Anderson K.E., Borgida A., Bracci P.M., Bueno-de-Mesquita H.B., Cotterchio M., Dai Q., Duell E.J., Fontham E.H., Gallinger S., Holly E.A., Ji B.T., Kurtz R.C., La Vecchia C., Lowenfels A.B., Luckett B., Ludwig E., Petersen G.M., Polesel J., Seminara D., Strayer L., Talamini R., Pancreatic Cancer Case-Control Consortium Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Am. J. Epidemiol. 2013, 178:691-700. 10.1093/aje/kwt052.
128. Olsson N., Piek E., ten Dijke P., Nilsson G. Human mast cell migration in response to members of the transforming growth factor-beta family. J. Leukoc. Biol. 2000, 67:350-356.
129. Oschatz C., Maas C., Lecher B., Jansen T., Bjorkqvist J., Tradler T., Sedlmeier R., Burfeind P., Cichon S., Hammerschmidt S., Muller-Esterl W., Wuillemin W.A., Nilsson G., Renne T. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011, 34:258-268. 10.1016/j.immuni.2011.02.008.
130. + T cells through production of leukotriene B4. Nat. Immunol. 2003, 4:974-981. 10.1038/ni971.
131. Ownby D.R., Ownby H.E., Bailey J., Frederick J., Tilley B., Brooks S.C., Russo J., Heppner G., Brennan M. Presurgical serum immunoglobulin concentrations and the prognosis of operable breast cancer in women. J. Natl. Cancer Inst. 1985, 75:655-663.
132. Piconese S., Gri G., Tripodo C., Musio S., Gorzanelli A., Frossi B., Pedotti R., Pucillo C.E., Colombo M.P. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009, 114:2639-2648. 10.1182/blood-2009-05-220004.
133. Piliponsky A.M., Chen C.C., Rios E.J., Treuting P.M., Lahiri A., Abrink M., Pejler G., Tsai M., Galli S.J. The chymase mouse mast cell protease 4 degrades TNF, limits inflammation, and promotes survival in a model of sepsis. Am. J. Pathol. 2012, 181:875-886. 10.1016/j.ajpath.2012.05.013.
134. Pittoni P., Piconese S., Tripodo C., Colombo M.P. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 2011, 30:757-769. 10.1038/onc.2010.494.
135. Polajeva J., Sjosten A.M., Lager N., Kastemar M., Waern I., Alafuzoff I., Smits A., Westermark B., Pejler G., Uhrbom L., Tchougounova E. Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PLoS ONE 2011, 6:e25222. 10.1371/journal.pone.0025222.
136. Rabenhorst A., Schlaak M., Heukamp L.C., Forster A., Theurich S., von Bergwelt-Baildon M., Buttner R., Kurschat P., Mauch C., Roers A., Hartmann K. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 2012, 120:2042-2054. 10.1182/blood-2012-03-415638.
137. Rajput A.B., Turbin D.A., Cheang M.C., Voduc D.K., Leung S., Gelmon K.A., Gilks C.B., Huntsman D.G. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4444 cases. Breast Cancer Res. Treat. 2008, 107:249-257. 10.1007/s10549-007-9546-3.
138. Ribatti D., Vacca A., Ria R., Marzullo A., Nico B., Filotico R., Roncali L., Dammacco F. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur. J. Cancer 2003, 39:666-674.
139. Romero A.I., Thoren F.B., Brune M., Hellstrand K. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. Br. J. Haematol. 2006, 132:91-98. 10.1111/j.1365-2141.2005.05842.x.
140. Royer B., Varadaradjalou S., Saas P., Gabiot A.C., Kantelip B., Feger F., Guillosson J.J., Kantelip J.P., Arock M. Autocrine regulation of cord blood-derived human mast cell activation by IL-10. J. Allergy Clin. Immunol. 2001, 108:80-86. 10.1067/mai.2001.115753.
141. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol. Metab. 2002, 13:128-134.
142. Rudich N., Ravid K., Sagi-Eisenberg R. Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation. Front. Immunol. 2012, 3:134. 10.3389/fimmu.2012.00134.
143. Salamon P., Shoham N.G., Gavrieli R., Wolach B., Mekori Y.A. Human mast cells release Interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 2005, 60:1316-1319. 10.1111/j.1398-9995.2005.00886.x.
144. Saleem S.J., Martin R.K., Morales J.K., Sturgill J.L., Gibb D.R., Graham L., Bear H.D., Manjili M.H., Ryan J.J., Conrad D.H. Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J. Immunol. 2012, 189:511-515. 10.4049/jimmunol.1200647.
145. Samoszuk M., Corwin M.A. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int. J. Cancer 2003, 107:159-163. 10.1002/ijc.11340.
146. Samoszuk M., Corwin M.A. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec). Int. J. Cancer 2003, 106:647-652. 10.1002/ijc.11282.
147. Samoszuk M., Kanakubo E., Chan J.K. Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer 2005, 5:121. 10.1186/1471-2407-5-121.
148. Schiemann F., Brandt E., Gross R., Lindner B., Mittelstadt J., Sommerhoff C.P., Schulmistrat J., Petersen F. The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4. J. Immunol. 2009, 183:2223-2231. 10.4049/jimmunol.0803587.
149. Schwartzbaum J., Ding B., Johannesen T.B., Osnes L.T., Karavodin L., Ahlbom A., Feychting M., Grimsrud T.K. Association between prediagnostic IgE levels and risk of glioma. J. Natl. Cancer Inst. 2012, 104:1251-1259. 10.1093/jnci/djs315.
150. Sherman P.W., Holland E., Sherman J.S. Allergies: their role in cancer prevention. Q. Rev. Biol. 2008, 83:339-362.
151. Shime H., Matsumoto M., Oshiumi H., Tanaka S., Nakane A., Iwakura Y., Tahara H., Inoue N., Seya T. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2066-2071. 10.1073/pnas.1113099109.
152. Shime H., Kojima A., Maruyama A., Saito Y., Oshiumi H., Matsumoto M., Seya T. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J. Innate Immun. 2013, 10.1159/000355126.
153. Shirota Y., Shirota H., Klinman D.M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. Immunol. 2012, 188:1592-1599. 10.4049/jimmunol.1101304.
154. Singer J., Jensen-Jarolim E. IgE-based immunotherapy of cancer: challenges and chances. Allergy 2013, 10.1111/all.12276.
155. Soucek L., Lawlor E.R., Soto D., Shchors K., Swigart L.B., Evan G.I. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 2007, 13:1211-1218. 10.1038/nm1649.
156. Soule B.P., Brown J.M., Kushnir-Sukhov N.M., Simone N.L., Mitchell J.B., Metcalfe D.D. Effects of gamma radiation on FcepsilonRI and TLR-mediated mast cell activation. J. Immunol. 2007, 179:3276-3286.
157. Subramanian H., Gupta K., Guo Q., Price R., Ali H. Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to receptor phosphorylation, desensitization, and internalization. J. Biol. Chem. 2011, 286:44739-44749. 10.1074/jbc.M111.277152.
158. Sumbayev V.V., Yasinska I., Oniku A.E., Streatfield C.L., Gibbs B.F. Involvement of hypoxia-inducible factor-1 in the inflammatory responses of human LAD2 mast cells and basophils. PLoS ONE 2012, 7:e34259. 10.1371/journal.pone.0034259.
159. Taipale J., Lohi J., Saarinen J., Kovanen P.T., Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 1995, 270:4689-4696.
160. Takanami I., Takeuchi K., Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000, 88:2686-2692.
161. Takeda K., Nakayama M., Sakaki M., Hayakawa Y., Imawari M., Ogasawara K., Okumura K., Smyth M.J. IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J. Leukoc. Biol. 2011, 90:777-785. 10.1189/jlb.0411208.
162. Takeuchi K., Koike K., Kamijo T., Ishida S., Nakazawa Y., Kurokawa Y., Sakashita K., Kinoshita T., Matsuzawa S., Shiohara M., Yamashita T., Nakajima M., Komiyama A. STI571 inhibits growth and adhesion of human mast cells in culture. J. Leukoc. Biol. 2003, 74:1026-1034. 10.1189/jlb.0602284.
163. Tatsuta M., Iishi H., Ichii M., Noguchi S., Yamamura H., Taniguchi H. Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N'-nitro-N-nitrosoguanidine. J. Natl. Cancer Inst. 1986, 76:277-281.
164. Teo P.Z., Utz P.J., Mollick J.A. Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1. Cancer Immunol. Immunother. 2012, 61:2295-2309. 10.1007/s00262-012-1299-0.
165. Theiner G., Gessner A., Lutz M.B. The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo. Immunobiology 2006, 211:463-472. 10.1016/j.imbio.2006.05.020.
166. Theoharides T.C., Alysandratos K.D., Angelidou A., Delivanis D.A., Sismanopoulos N., Zhang B., Asadi S., Vasiadi M., Weng Z., Miniati A., Kalogeromitros D. Mast cells and inflammation. Biochim. Biophys. Acta 2012, 1822:21-33. 10.1016/j.bbadis.2010.12.014.
167. Toh B., Wang X., Keeble J., Sim W.J., Khoo K., Wong W.C., Kato M., Prevost-Blondel A., Thiery J.P., Abastado J.P. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9:e1001162. 10.1371/journal.pbio.1001162.
168. Tomita K., Nakamura E., Okabe S. Histamine regulates growth of malignant melanoma implants via H2 receptors in mice. Inflammopharmacology 2005, 13:281-289. 10.1163/156856005774423917.
169. Torres R., de Castellarnau C., Ferrer L.L., Puigdemont A., Santamaria L.F., de Mora F. Mast cells induce upregulation of P-selectin and intercellular adhesion molecule 1 on carotid endothelial cells in a new in vitro model of mast cell to endothelial cell communication. Immunol. Cell Biol. 2002, 80:170-177. 10.1046/j.1440-1711.2002.01069.x.
170. Tunis M.C., Dawicki W., Carson K.R., Wang J., Marshall J.S. Mast cells and IgE activation do not alter the development of oral tolerance in a murine model. J. Allergy Clin. Immunol. 2012, 130. 705-715 e1. 10.1016/j.jaci.2012.04.011.
171. Vacchelli E., Eggermont A., Sautes-Fridman C., Galon J., Zitvogel L., Kroemer G., Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013, 2:e25238. 10.4161/onci.25238.
172. Van Nguyen H., Di Girolamo N., Jackson N., Hampartzoumian T., Bullpitt P., Tedla N., Wakefield D. Ultraviolet radiation-induced cytokines promote mast cell accumulation and matrix metalloproteinase production: potential role in cutaneous lupus erythematosus. Scand. J. Rheumatol. 2011, 40:197-204. 10.3109/03009742.2010.528020.
173. Vanbervliet B., Akdis M., Vocanson M., Rozieres A., Benetiere J., Rouzaire P., Akdis C.A., Nicolas J.F., Hennino A. Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-gamma/IL-17 balance in T cell-mediated skin inflammation. J. Allergy Clin. Immunol. 2011, 127. 943-53.e1-10. 10.1016/j.jaci.2010.12.002.
174. Venkatesha R.T., Berla Thangam E., Zaidi A.K., Ali H. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol. Immunol. 2005, 42:581-587. 10.1016/j.molimm.2004.09.009.
175. Vosskuhl K., Greten T.F., Manns M.P., Korangy F., Wedemeyer J. Lipopolysaccharide-mediated mast cell activation induces IFN-gamma secretion by NK cells. J. Immunol. 2010, 185:119-125. 10.4049/jimmunol.0902406.
176. Wang Z., Macleod D.T., Di Nardo A. Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses. J. Immunol. 2012, 189:1551-1558. 10.4049/jimmunol.1200471.
177. Wang B., Li L., Liao Y., Li J., Yu X., Zhang Y., Xu J., Rao H., Chen S., Zhang L., Zheng L. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 2013, 62:1575-1585. 10.1007/s00262-013-1460-4.
178. Wasiuk A., Dalton D.K., Schpero W.L., Stan R.V., Conejo-Garcia J.R., Noelle R.J. Mast cells impair the development of protective anti-tumor immunity. Cancer Immunol. Immunother. 2012, 61:2273-2282. 10.1007/s00262-012-1276-7.
179. Watson S.A., Wilkinson L.J., Robertson J.F., Hardcastle J.D. Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut 1993, 34:1091-1096.
180. Wedemeyer J., Galli S.J. Decreased susceptibility of mast cell-deficient Kit(W)/Kit(W-v) mice to the development of 1,2-dimethylhydrazine-induced intestinal tumors. Lab. Invest. 2005, 85:388-396. 10.1038/labinvest.3700232.
181. Weller C.L., Collington S.J., Brown J.K., Miller H.R., Al-Kashi A., Clark P., Jose P.J., Hartnell A., Williams T.J. Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J. Exp. Med. 2005, 201:1961-1971. 10.1084/jem.20042407.
182. Weller C.L., Collington S.J., Hartnell A., Conroy D.M., Kaise T., Barker J.E., Wilson M.S., Taylor G.W., Jose P.J., Williams T.J. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11712-11717. 10.1073/pnas.0701700104.
183. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byrne K.J., Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:8959-8967. 10.1200/JCO.2005.01.4910.
184. Woolhiser M.R., Brockow K., Metcalfe D.D. Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin. Immunol. 2004, 110:172-180. 10.1016/j.clim.2003.11.007.
185. Xia Q., Wu X.J., Zhou Q., Jing Z., Hou J.H., Pan Z.Z., Zhang X.S. No relationship between the distribution of mast cells and the survival of stage IIIB colon cancer patients. J. Transl. Med. 2011, 9:88. 10.1186/1479-5876-9-88.
186. Yang Z., Zhang B., Li D., Lv M., Huang C., Shen G.X., Huang B. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE 2010, 5:e8922. 10.1371/journal.pone.0008922.
187. + immature myeloid cells. Nat. Med. 2011, 17:87-95. 10.1038/nm.2278.
188. Yano H., Kinuta M., Tateishi H., Nakano Y., Matsui S., Monden T., Okamura J., Sakai M., Okamoto S. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 1999, 2:26-32.
189. Yoshioka M., Fukuishi N., Kubo Y., Yamanobe H., Ohsaki K., Kawasoe Y., Murata M., Ishizumi A., Nishii Y., Matsui N., Akagi M. Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. Biol. Pharm. Bull. 2008, 31:212-216.
190. Zhang W., Stoica G., Tasca S.I., Kelly K.A., Meininger C.J. Modulation of tumor angiogenesis by stem cell factor. Cancer Res. 2000, 60:6757-6762.
191. Zhang J., Alcaide P., Liu L., Sun J., He A., Luscinskas F.W., Shi G.P. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS ONE 2011, 6:e14525. 10.1371/journal.pone.0014525.
192. Zhao W., Oskeritzian C.A., Pozez A.L., Schwartz L.B. Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. J. Immunol. 2005, 175:2635-2642.
193. Zhu X.Q., Lv J.Q., Lin Y., Xiang M., Gao B.H., Shi Y.F. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells. Gynecol. Oncol. 2007, 105:650-656. 10.1016/j.ygyno.2007.01.046.
194. Zoglmeier C., Bauer H., Norenberg D., Wedekind G., Bittner P., Sandholzer N., Rapp M., Anz D., Endres S., Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 2011, 17:1765-1775. 10.1158/1078-0432.CCR-10-2672.
195. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 10:248-256. 10.1038/nri2742.